[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334068-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334068-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ras-signaling-in-carcinogenesis-cancer-therapy-and-resistance-mechanisms-review","RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms - Review","","Variants in the RAS family (HRAS, NRAS, KRAS) are among the most common cancer mutations, present in about 19% of patients and linked to poor clinical outcomes. For years, KRAS was considered undruggable, but drug-design advances now enable RAS-targeting therapies, including approved direct KRASG12C inhibitors for KRASG12C-mutant NSCLC. The review summarizes RAS signaling roles, RAS mutations, therapeutic strategies, and de novo, acquired, and adaptive resistance across malignancies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ras-signaling-in-carcinogenesis-cancer-therapy-and-resistance-mechanisms-review/334068/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ras-signaling-in-carcinogenesis-cancer-therapy-and-resistance-mechanisms-review/334068.png","ImageObject",300,407,{"name":42,"@type":43},"Skyler","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which RAS family variants are discussed and how common are they in cancer?","Question",{"text":63,"@type":64},"The review covers HRAS, NRAS, and KRAS variants, which occur in about 19% of cancer patients.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why was KRAS historically considered undruggable?",{"text":68,"@type":64},"It was viewed as undruggable because its mutant isoforms lacked suitable small-molecule binding sites.",{"name":70,"@type":61,"acceptedAnswer":71},"What resistance categories does the review emphasize?",{"text":72,"@type":64},"It emphasizes de novo resistance, acquired resistance, and adaptive resistance across multiple malignancies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334068,1790181970,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":4},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Yang and Wu Journal of Hematology & Oncology (2024) 17:108 [https://doi.org/10.1186/s13045-024-01631-9](https://doi.org/10.1186/s13045-024-01631-9)  \nJournal of Hematology & Oncology  \nREVIEW Open Access  \nRAS signaling in carcinogenesis, cancer therapy and resistance mechanisms  \nXiaojuan Yang 1 and HongWu 1,2*  \nAbstract  \nVariants in the RAS family (HRAS, NRAS and KRAS) are among the most common mutations found in cancer. About 19% patients with cancer harbor RAS mutations, which are typically associated with poor clinical outcomes. Over the past four decades, KRAS has long been considered an undruggable target due to the absence of suitable small-molecule binding sites within its mutant isoforms. However, recent advancements in drug design have made RAS-targeting therapies viable, particularly with the approval of direct KRASG12C inhibitors, such as sotorasib and adagrasib, for treating non-small cell lung cancer (NSCLC) with KRASG12C mutations. Other KRAS-mutant inhibitors targeting KRASG12D are currently being developed for use in the clinic, particularly for treating highly refractory malignancies like pancreatic cancer. Herein, we provide an overview of RAS signaling, further detailing the roles of the RAS signaling pathway in carcinogenesis. This includes a summary of RAS mutations in human cancers and an emphasis on therapeutic approaches, as well as de novo, acquired, and adaptive resistance in various malignancies.  \nIntroduction to RAS: Its structure and mutations in cancer  \nRAS was firstly identified as a virus-encoded gene by Jennifer Harvey and her colleagues in 1964 [1]. It was regarded as an oncogene, being one of the most frequently mutated genes in human cancer [2, 3]. Mutationally activated RAS is present in approximately one in five human cancers.  \nThe RAS gene family includes three members: HRAS, NRAS, and KRAS [4]. Indeed, RAS proteins are implicated in a variety of biological responses, including cell  \n*Correspondence:  \nHongWu  \n[wuhong@scu.edu.cn](wuhong@scu.edu.cn)  \n1Liver Digital Transformation Research Laboratory, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu,  \nSichuan 610041, P. R. China  \n2Liver Transplantation Center, Liver Digital Transformation Research Laboratory, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan 610041, P. R. China  \nproliferation, migration, growth arrest, senescence, differentiation, apoptosis, and survival [2]. Cancer cells with RAS mutations display more aggressive phenotypes [5]. As a result, patients with RAS mutations are more likely to experience poor prognosis and shorter survival compared to those with wild-type (WT) RAS [6, 7].  \nAlterations in components of the RAS signaling pathway, especially the RAS proteins that serve as central mediators, have significant consequences in various cancers, particularly in NSCLC, colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC) [8]. Over the past four decades, significant efforts from both academia and industry have been directed toward developing drugs targeting RAS proteins for cancer therapy [9]. This decades-long difficulties for drug design are due to several factors: (1) Inhibitors must selectively target the dynamic conformational changes that RAS undergoes as it cycles between the GTP-bound (RAS (ON)) state and the GDP-bound (RAS (OFF)) state, each characterized by distinct structural features; (2) RAS proteins exhibit a strong affinity for GTP, compounded by the  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) an","cbCaimn06ruyuIsl","https://ap.wps.com/l/cbCaimn06ruyuIsl","pdf",3968229,31,"English","# Introduction to RAS: Its structure and mutations in cancer","[{\"question\":\"Which RAS family variants are discussed and how common are they in cancer?\",\"answer\":\"The review covers HRAS, NRAS, and KRAS variants, which occur in about 19% of cancer patients.\"},{\"question\":\"Why was KRAS historically considered undruggable?\",\"answer\":\"It was viewed as undruggable because its mutant isoforms lacked suitable small-molecule binding sites.\"},{\"question\":\"What resistance categories does the review emphasize?\",\"answer\":\"It emphasizes de novo resistance, acquired resistance, and adaptive resistance across multiple malignancies.\"}]","RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms - Review | PDF",1790005184,78]